A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing Delirium After Hip Fracture Repair Surgery
Dexmedetomidine is currently approved for use for 24 hours in patients on ventilators in the ICU. This study is to determine whether or not dexmedetomidine can prevent delirium after hip fracture repair surgery. Study participation will last from within 72 hours of surgery to 3 days after surgery, continue throughout surgery and up to 2 hours after surgery. Delirium will be assessed prior to surgery and for 72 hours after surgery. This assessment will consist of questions to determine memory and thought process. Thirty days after surgery, questions will be asked regarding quality of life and hospital billing.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Prevention
|Official Title:||A Phase III,Randomized, Double-Blind, Placebo-Controlled, Two-Arm Parallel, Multicenter Study Evaluating the Efficacy and Safety of Dexmedetomidine in the Prevention of Postoperative Delirium in Subjects Undergoing Surgery for Fractured Hip With General Anesthesia|
- Postoperative delirium
- Duration and percentage of Delirium, amount of sedation and analgesics administered, mortality, length of hospital stay and discharge status
|Study Start Date:||April 2007|
|Study Completion Date:||November 2007|
Postoperative delirium is an acute decline in cognition and attention which is usually transient but when delirium persists it can impact cognitive function, morbidity and morality. There are no drugs that are currently approved to prevent the onset of delirium but dexmedetomidine has the potential to meet this unmet medical need. Hip fractures, unfortunately are frequent occurrences in the elderly population and the elderly are more prone to developing delirium after surgery.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00460473
Show 29 Study Locations